Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2010

Open Access 01-12-2010 | Editorial

Sweet fruit from a poisonous kiss

Author: Delong Liu

Published in: Journal of Hematology & Oncology | Issue 1/2010

Login to get access

Excerpt

Acute promyelocytic leukemia (APL), once a rapidly fatal disease, has become most curable of all leukemias, thanks to the two Chinese wonder drugs, all-trans retinoid acid and arsenic trioxide (AT). PML-RXARα fusion protein is the hallmark and driving force of APL. In the April 9th issue of the journal, Science, Zhang et al. provided new and convincing evidence on how AT, an ancient poisonous medicine, plays the tricks on the oncoprotein, PML-RARα, and sheds lights on how a poisonous kiss leads to the sweet fruit [1]. …
Literature
1.
Zhang X-W, Yan Xiao-Jing, Zhou Zi-Ren, Yang Fei-Fei, Wu Zi-Yu, Sun Hong-Bin, Liang Wen-Xue, Song Ai-Xin, Lallemand-Breitenbach Valérie, Jeanne Marion, Zhang Qun-Ye, Yang Huai-Yu, Huang Qiu-Hua, Zhou Guang-Biao, Tong Jian-Hua, Zhang Yan, Wu Ji-Hui, Hu Hong-Yu, de Thé Hugues, Chen Sai-Juan, Chen Zhu: Arsenic trioxide controls the fate of the PML-RARα oncoprotein by directly binding PML. Science. 2010, 328: 240-243. 10.1126/science.1183424.CrossRefPubMed
Metadata
Title
Sweet fruit from a poisonous kiss
Author
Delong Liu
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2010
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-3-19

Other articles of this Issue 1/2010

Journal of Hematology & Oncology 1/2010 Go to the issue

Research

Mitochondrial and endoplasmic reticulum stress pathways cooperate in zearalenone-induced apoptosis of human leukemic cells

Case report

Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report

Case report

Ring chromosome 18 abnormality in acute myelogenous leukemia: the clinical dilemma

Case report

Pancytopenia associated with clonazepam

Review

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib

Research

RRM1 single nucleotide polymorphism -37C→A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits